{"organizations": [], "uuid": "52b26ef06819dd40712394e3dc503755cfbab2c3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-janssen-announces-fda-breakthrough/brief-janssen-announces-fda-breakthrough-therapy-designation-for-erdafitinib-in-the-treatment-of-metastatic-urothelial-cancer-idUSASC09SF3", "country": "US", "domain_rank": 408, "title": "BRIEF-Janssen Announces FDA Breakthrough Therapy Designation For Erdafitinib In The Treatment Of Metastatic Urothelial Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-15T14:24:00.000+02:00", "replies_count": 0, "uuid": "52b26ef06819dd40712394e3dc503755cfbab2c3"}, "author": "", "url": "https://www.reuters.com/article/brief-janssen-announces-fda-breakthrough/brief-janssen-announces-fda-breakthrough-therapy-designation-for-erdafitinib-in-the-treatment-of-metastatic-urothelial-cancer-idUSASC09SF3", "ord_in_thread": 0, "title": "BRIEF-Janssen Announces FDA Breakthrough Therapy Designation For Erdafitinib In The Treatment Of Metastatic Urothelial Cancer", "locations": [], "entities": {"persons": [{"name": "erda", "sentiment": "negative"}, {"name": "janssen", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "treatment of metastatic urothelial cancer reuters staff", "sentiment": "none"}, {"name": "min read   johnson & johnson", "sentiment": "none"}, {"name": "erdafitinib", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 26 PM / Updated 20 minutes ago BRIEF-Janssen Announces FDA Breakthrough Therapy Designation For Erdafitinib In The Treatment Of Metastatic Urothelial Cancer Reuters Staff 1 Min Read   Johnson & Johnson: * JANSSEN ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ERDAFITINIB IN THE TREATMENT OF METASTATIC UROTHELIAL CANCER * JANSSEN PHARMACEUTICAL - BREAKTHROUGH THERAPY DESIGNATION BASED ON DATA FROM MULTICENTER, OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ERDAFITINIB Source text for Eikon:  ", "external_links": [], "published": "2018-03-15T14:24:00.000+02:00", "crawled": "2018-03-15T14:42:09.025+02:00", "highlightTitle": ""}